Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity

Anthony R. Cillo, Carly Cardello, Feng Shan, Lilit Karapetyan, Sheryl Kunning, Cindy Sander, Elizabeth Rush, Arivarasan Karunamurthy, Ryan C. Massa, Anjali Rohatgi, Creg J. Workman, John M. Kirkwood, Tullia C. Bruno, Dario A.A. Vignali

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

Relatlimab (rela; anti-LAG-3) plus nivolumab (nivo; anti-PD-1) is safe and effective for treatment of advanced melanoma. We designed a trial (NCT03743766) where advanced melanoma patients received rela, nivo, or rela+nivo to interrogate the immunologic mechanisms of rela+nivo. Analysis of biospecimens from this ongoing trial demonstrated that rela+nivo led to enhanced capacity for CD8+ T cell receptor signaling and altered CD8+ T cell differentiation, leading to heightened cytotoxicity despite the retention of an exhaustion profile. Co-expression of cytotoxic and exhaustion signatures was driven by PRDM1, BATF, ETV7, and TOX. Effector function was upregulated in clonally expanded CD8+ T cells that emerged after rela+nivo. A rela+nivo intratumoral CD8+ T cell signature was associated with a favorable prognosis. This intratumoral rela+nivo signature was validated in peripheral blood as an elevated frequency of CD38+TIM3+CD8+ T cells. Overall, we demonstrated that cytotoxicity can be enhanced despite the retention of exhaustion signatures, which will inform future therapeutic strategies.

Original languageEnglish
Pages (from-to)4373-4388.e15
JournalCell
Volume187
Issue number16
DOIs
StatePublished - Aug 8 2024

Keywords

  • CD8 T cell transcriptional profiles
  • LAG-3
  • PD-1
  • T cell exhaustion
  • advanced melanoma
  • antitumor immunity
  • checkpoint blockade
  • combination immunotherapy
  • inhibitory receptors

Fingerprint

Dive into the research topics of 'Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity'. Together they form a unique fingerprint.

Cite this